![]() |
|
|||
|
LOS ANGELES — Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin cancer.
|
| Thread Tools | |
| Display Modes | |
|
|